

Johann Sebastian de Bono

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3369798/johann-sebastian-de-bono-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

692 papers	59,643 citations	110 h-index	235 g-index
843 ext. papers	71,962 ext. citations	8.4 avg, IF	7.4 L-index

#	Paper	IF	Citations
692	Increased survival with enzalutamide in prostate cancer after chemotherapy. <i>New England Journal of Medicine</i> , 2012 , 367, 1187-97	59.2	3075
691	Abiraterone and increased survival in metastatic prostate cancer. <i>New England Journal of Medicine</i> , 2011 , 364, 1995-2005	59.2	3019
690	Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. <i>New England Journal of Medicine</i> , 2009 , 361, 123-34	59.2	2786
689	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. <i>Lancet, The</i> , 2010 , 376, 1147-54	40	2311
688	Abiraterone in metastatic prostate cancer without previous chemotherapy. <i>New England Journal of Medicine</i> , 2013 , 368, 138-48	59.2	1940
687	Enzalutamide in metastatic prostate cancer before chemotherapy. <i>New England Journal of Medicine</i> , 2014 , 371, 424-33	59.2	1892
686	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , 2015 , 161, 1215-1228	56.2	1765
685	Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 6302-9	12.9	1685
684	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015 , 373, 1697-708	59.2	1345
683	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1163-77	40	1115
682	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology, The</i> , 2012 , 13, 983-92	21.7	965
681	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017 , 377, 338-351	59.2	898
680	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology, The</i> , 2015 , 16, 152-60	21.7	856
679	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 443-53	59.2	791
678	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2512-9	2.2	737
677	Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4563-71	2.2	713
676	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. <i>Science</i> , 2018 , 359, 920-926	33.3	712

675	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1402-18 ^{2.2}	666
674	Prostate cancer. <i>Lancet, The</i> , 2016 , 387, 70-82	40 645
673	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 2091-2102	59.2 550
672	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. <i>Lancet Oncology, The</i> , 2009 , 10, 233-9	21.7 476
671	Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3742-8	2.2 469
670	Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. <i>Cancer Research</i> , 2009 , 69, 2912-8	10.1 466
669	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4688-95	2.2 444
668	Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. <i>Current Opinion in Pharmacology</i> , 2008 , 8, 393-412	5.1 439
667	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology, The</i> , 2013 , 14, 882-92	21.7 410
666	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , 2018 , 50, 645-651	36.3 380
665	Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1496-501	2.2 345
664	Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. <i>Science Translational Medicine</i> , 2016 , 8, 362ps17	17.5 343
663	Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1489-95	2.2 331
662	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018 , 73, 178-211	10.2 313
661	Plasma AR and abiraterone-resistant prostate cancer. <i>Science Translational Medicine</i> , 2015 , 7, 312re10	17.5 301
660	Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1348-55	2.2 295
659	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3965-72	2.2 291
658	Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. <i>Lancet Oncology, The</i> , 2010 , 11, 129-35	21.7 280

657	Targeting the PI3K/AKT pathway for the treatment of prostate cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 4799-805	12.9	272
656	Translating cancer research into targeted therapeutics. <i>Nature</i> , 2010 , 467, 543-9	50.4	269
655	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. <i>Cell</i> , 2018 , 173, 1770-1782.e14	56.2	256
654	Tumor clone dynamics in lethal prostate cancer. <i>Science Translational Medicine</i> , 2014 , 6, 254ra125	17.5	256
653	Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). <i>European Urology</i> , 2015 , 67, 1028-1038	10.2	255
652	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 162-174	21.7	244
651	Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. <i>Journal of Pathology</i> , 2013 , 229, 422-9	9.4	235
650	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline Mutations and Selected Sporadic Cancers. <i>Cancer Discovery</i> , 2017 , 7, 620-629	24.4	232
649	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , 2017 , 7, 1006-1017	24.4	232
648	Envisioning the future of early anticancer drug development. <i>Nature Reviews Cancer</i> , 2010 , 10, 514-23	31.3	232
647	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology, The</i> , 2012 , 13, 1210-7	21.7	225
646	Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 645-657	59.2	224
645	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2013 , 31, 760-8	4.3	220
644	Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 5834-40	12.9	220
643	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 2506-2518	59.2	219
642	A decade of clinical development of PARP inhibitors in perspective. <i>Annals of Oncology</i> , 2019 , 30, 1437-1447	14.3	218
641	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1652-9	2.2	217
640	First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2015 , 21, 77-86	12.9	217

639	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 395-405	2.2	216
638	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , 2019 , 75, 88-99	10.2	216
637	A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovotine), administered twice daily for 7 days every 21 days. <i>British Journal of Cancer</i> , 2007 , 96, 29-37	8.7	212
636	Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. <i>Clinical Cancer Research</i> , 2007 , 13, 6187-94	12.9	212
635	Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2647-57	2.2	212
634	Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. <i>Journal of Clinical Oncology</i> , 2003 , 21, 211-22	2.2	209
633	Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. <i>Cancer Research</i> , 2012 , 72, 2176-82	10.1	205
632	Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021 , 385, 1091-1103	59.2	202
631	Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 507-16	5.6	199
630	Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. <i>Annals of Oncology</i> , 2012 , 23, 2943-2947	10.3	195
629	Development of therapeutic combinations targeting major cancer signaling pathways. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1592-605	2.2	194
628	Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). <i>European Urology</i> , 2014 , 66, 815-25	10.2	186
627	CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. <i>Nature</i> , 2018 , 559, 285-289	50.4	178
626	A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1041-50	3.5	175
625	Steroid hormone receptors in prostate cancer: a hard habit to break?. <i>Cancer Cell</i> , 2009 , 16, 458-62	24.3	173
624	Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. <i>Clinical Cancer Research</i> , 2007 , 13, 3611-6	12.9	171
623	Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , 2013 , 14, 1307-16	21.7	169
622	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3005-13	2.2	163

621	IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. <i>Nature</i> , 2018 , 559, 363-369	50.4	163
620	Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. <i>Clinical Cancer Research</i> , 2019 , 25, 928-936	12.9	161
619	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. <i>Journal of Clinical Investigation</i> , 2019 , 129, 192-208	15.9	157
618	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
617	Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. <i>BJU International</i> , 2005 , 96, 1241-6	5.6	155
616	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. <i>Clinical Cancer Research</i> , 2015 , 21, 4586-96	12.9	154
615	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. <i>Lancet Oncology</i> , 2014 , 15, 1147-56	21.7	154
614	Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 765-73	3.5	153
613	Circulating tumor cells: a multifunctional biomarker. <i>Clinical Cancer Research</i> , 2014 , 20, 2553-68	12.9	151
612	METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. <i>European Urology</i> , 2017 , 71, 81-92	10.2	150
611	Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m) and the Currently Approved Dose (25 mg/m) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3198-3206	2.2	147
610	Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. <i>Ca-A Cancer Journal for Clinicians</i> , 2011 , 61, 31-49	220.7	144
609	Reovirus activates human dendritic cells to promote innate antitumor immunity. <i>Journal of Immunology</i> , 2008 , 180, 6018-26	5.3	144
608	PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. <i>European Urology</i> , 2015 , 67, 795-802	10.2	143
607	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 2345-2357	59.2	143
606	Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. <i>Clinical Cancer Research</i> , 2008 , 14, 259-69	12.9	142
605	Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2692-6	2.2	139
604	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 509-21	21.7	138

603	Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. <i>Cancer Research</i> , 2009 , 69, 4937-40	10.1	134
602	Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. <i>Cancer Journal (Sudbury, Mass.)</i> , 2009 , 15, 406-20	2.2	133
601	DNA Repair in Prostate Cancer: Biology and Clinical Implications. <i>European Urology</i> , 2017 , 71, 417-425	10.2	132
600	New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. <i>Clinical Cancer Research</i> , 2011 , 17, 1649-57	12.9	130
599	A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2008 , 14, 2075-81	12.9	130
598	Visceral disease in castration-resistant prostate cancer. <i>European Urology</i> , 2014 , 65, 270-273	10.2	126
597	Evolution of androgen receptor targeted therapy for advanced prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 365-76	19.4	125
596	Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. <i>British Journal of Cancer</i> , 2008 , 98, 1029-33	8.7	124
595	Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018 , 36, 572-580	2.2	123
594	Sequencing of agents in castration-resistant prostate cancer. <i>Lancet Oncology, The</i> , 2015 , 16, e279-92	21.7	123
593	Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. <i>PLoS ONE</i> , 2012 , 7, e47020	3.7	119
592	The changing therapeutic landscape of castration-resistant prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 597-610	19.4	118
591	Update on tubulin-binding agents. <i>Pathologie Et Biologie</i> , 2006 , 54, 72-84		117
590	Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. <i>European Urology</i> , 2014 , 66, 459-65	10.2	116
589	Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. <i>European Urology</i> , 2019 , 76, 469-478	10.2	114
588	Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2011 , 17, 3420-30	12.9	114
587	Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1729-37	9.7	113
586	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018 , 50, 682-692	36.3	112

585	New therapies for castration-resistant prostate cancer: efficacy and safety. <i>European Urology</i> , 2011 , 60, 279-90	10.2	111
584	SPOP mutation leads to genomic instability in prostate cancer. <i>ELife</i> , 2015 , 4,	8.9	110
583	Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. <i>JAMA Oncology</i> , 2016 , 2, 348-57	13.4	108
582	Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naïve patients with hormone-refractory prostate cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 257-62	2.2	108
581	Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2008 , 14, 6663-73	12.9	106
580	Antitumor activity in RAS-driven tumors by blocking AKT and MEK. <i>Clinical Cancer Research</i> , 2015 , 21, 739-48	12.9	104
579	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 1	22.4	104
578	Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. <i>Clinical Cancer Research</i> , 2013 , 19, 5485-93	12.9	103
577	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. <i>Molecular Cell</i> , 2015 , 58, 925-34	34.6	102
576	Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3391-9	2.2	101
575	Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. <i>Journal of Clinical Oncology</i> , 2015 , 33, 723-31	2.2	100
574	Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. <i>Cancer</i> , 2014 , 120, 3346-52	6.4	98
573	Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1728-35	2.2	98
572	Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. <i>Lancet Oncology</i> , 2012 , 13, 1114-24	21.7	97
571	Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. <i>European Journal of Cancer</i> , 2010 , 46, 9-20	7.5	95
570	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. <i>Trials</i> , 2012 , 13, 168	2.8	94
569	Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1356-63	2.2	92
568	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. <i>Clinical Cancer Research</i> , 2015 , 21, 3412-9	12.9	92

567	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. <i>European Urology</i> , 2016 , 70, 985-992	10.2	92
566	Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2009 , 15, 3177-83	12.9	92
565	CYP17 inhibition as a hormonal strategy for prostate cancer. <i>Nature Reviews Urology</i> , 2008 , 5, 610-20		91
564	Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2791-8	2.2	90
563	Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. <i>Clinical Cancer Research</i> , 2010 , 16, 6150-8	12.9	90
562	Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016 , 70, 599-608	10.2	90
561	A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 581-8	12.9	88
560	Alternative splicing in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 663-675	19.4	87
559	Utilizing circulating tumor cells: challenges and pitfalls. <i>Current Opinion in Genetics and Development</i> , 2011 , 21, 50-8	4.9	87
558	External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study. <i>Cytometry Part B - Clinical Cytometry</i> , 2011 , 80, 112-8	3.4	87
557	Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. <i>Clinical Cancer Research</i> , 2008 , 14, 912-23	12.9	86
556	Clinical anticancer drug development: targeting the cyclin-dependent kinases. <i>British Journal of Cancer</i> , 2005 , 92, 7-12	8.7	86
555	A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. <i>Clinical Cancer Research</i> , 2013 , 19, 900-8	12.9	85
554	Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6152-9	2.2	85
553	Genomics of lethal prostate cancer at diagnosis and castration resistance. <i>Journal of Clinical Investigation</i> , 2020 , 130, 1743-1751	15.9	85
552	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4441-4453	15.9	84
551	Managing Nonmetastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019 , 75, 285-293	10.2	83
550	A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2013 , 19, 4262-72	12.9	80

549	Therapy monitoring of skeletal metastases with whole-body diffusion MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2014 , 39, 1049-78	5.6	79
548	Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. <i>European Urology</i> , 2015 , 68, 317-24	10.2	78
547	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). <i>Clinical Cancer Research</i> , 2018 , 24, 3149-3162	12.9	77
546	Drug discovery in advanced prostate cancer: translating biology into therapy. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 699-718	64.1	77
545	Targeting CYP17: established and novel approaches in prostate cancer. <i>Current Opinion in Pharmacology</i> , 2008 , 8, 449-57	5.1	77
544	Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019 , 76, 719-728	10.2	75
543	Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 2874-84	12.9	75
542	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. <i>Clinical Cancer Research</i> , 2018 , 24, 5585-5593	12.9	74
541	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017 , 23, 5981-5992	12.9	73
540	PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. <i>British Journal of Cancer</i> , 2015 , 113, 1225-33	8.7	72
539	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018 , 73, 715-723	10.2	71
538	Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. <i>Nature Genetics</i> , 2018 , 50, 219-228	36.3	71
537	Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3944-50	2.2	71
536	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>European Urology</i> , 2018 , 73, 687-693	10.2	70
535	Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. <i>European Urology</i> , 2013 , 64, 300-6	10.2	70
534	Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018 , 8,	5.4	69
533	The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1609-17	6.1	68
532	Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. <i>European Journal of Cancer</i> , 2013 , 49, 3648-57	7.5	68

531	Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. <i>PLoS ONE</i> , 2013 , 8, e67148	3.7	68
530	Appraising iniparib, the PARP inhibitor that never was--what must we learn?. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 688-96	19.4	66
529	First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013 , 109, 2579-86	8.7	66
528	CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. <i>Annals of Oncology</i> , 2017 , 28, 1495-1507	10.3	64
527	Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 383-393	21.7	64
526	KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5007-5007	2.2	64
525	Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. <i>Cancer Research</i> , 2016 , 76, 2731-42	10.1	64
524	Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3195-3204	2.2	63
523	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkz093	4.6	62
522	Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. <i>Clinical Cancer Research</i> , 2014 , 20, 5672-85	12.9	61
521	Expression profiling of CD133+ and CD133- epithelial cells from human prostate. <i>Prostate</i> , 2008 , 68, 1007-24	4.2	60
520	Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for 24 weeks in Europe. <i>European Urology</i> , 2018 , 74, 37-45	10.2	59
519	Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. <i>Clinical Cancer Research</i> , 2018 , 24, 5635-5644	12.9	59
518	Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer. <i>Cell Reports</i> , 2019 , 28, 2156-2168.e5	10.6	59
517	A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. <i>European Urology</i> , 2015 , 67, 673-9	10.2	59
516	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology, The</i> , 2018 , 19, e696-e708	21.7	59
515	Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology, The</i> , 2017 , 18, 473-485	21.7	58
514	ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. <i>Clinical Cancer Research</i> , 2004 , 10, 7555-65	12.9	58

513	Differential impact of RB status on E2F1 reprogramming in human cancer. <i>Journal of Clinical Investigation</i> , 2018 , 128, 341-358	15.9	58
512	BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. <i>Cell Reports</i> , 2018 , 22, 796-808	10.6	57
511	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016 , 70, 675-683	10.2	57
510	Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. <i>Journal of the National Cancer Institute</i> , 2014 , 106, dju033	9.7	57
509	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. <i>Radiology</i> , 2017 , 283, 168-177	20.5	57
508	A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. <i>Clinical Cancer Research</i> , 2012 , 18, 2687-94	12.9	57
507	Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. <i>Drug Discovery Today</i> , 2010 , 15, 88-97	8.8	57
506	Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). <i>European Urology</i> , 2018 , 74, 283-291	10.2	54
505	Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. <i>Annals of Oncology</i> , 2013 , 24, 1416-8	10.3	54
504	Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3753-8	2.2	54
503	The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. <i>Clinical Cancer Research</i> , 2015 , 21, 2297-2304	12.9	53
502	A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3K α Isoform Inhibitor, in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2017 , 23, 5015-5023	12.9	51
501	Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. <i>European Journal of Cancer</i> , 2016 , 56, 93-100	7.5	50
500	Switching and withdrawing hormonal agents for castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , 2015 , 12, 37-47	5.5	49
499	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. <i>European Urology</i> , 2019 , 75, 184-192	10.2	49
498	Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2017 , 76, 36-44	7.5	48
497	Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. <i>Clinical Cancer Research</i> , 2011 , 17, 3867-75	12.9	48
496	EpCAM and EpCAM circulating tumor cells in metastatic prostate and breast cancer patients. <i>Oncotarget</i> , 2018 , 9, 35705-35716	3.3	48

495	Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016 , 70, 724-731	10.2	47
494	Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2017 , 120, E30-E44	5.6	47
493	Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). <i>International Journal of Cancer</i> , 2018 , 143, 2584-2591	7.5	46
492	Rationale for Modernising Imaging in Advanced Prostate Cancer. <i>European Urology Focus</i> , 2017 , 3, 223-239	3.9	46
491	Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. <i>Clinical Cancer Research</i> , 2015 , 21, 1621-7	12.9	46
490	PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. <i>Annals of Oncology</i> , 2019 , 30, v881-v882	10.3	45
489	Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. <i>British Journal of Cancer</i> , 2014 , 111, 2248-53	8.7	45
488	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , 2021 , 11, 80-91	24.4	45
487	Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , 2017 , 71, 656-664	10.2	44
486	Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. <i>Investigational New Drugs</i> , 2014 , 32, 995-1004	4.3	44
485	FGF receptor inhibitors: role in cancer therapy. <i>Current Oncology Reports</i> , 2012 , 14, 111-9	6.3	44
484	Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. <i>Modern Pathology</i> , 2012 , 25, 902-10	9.8	44
483	Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA1-LBA1	2.2	44
482	Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer. <i>Cancer Research</i> , 2017 , 77, 3101-3112	10.1	43
481	Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. <i>Annals of Oncology</i> , 2012 , 23, 1241-1249	10.3	43
480	Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 2675-83	12.9	43
479	Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. <i>Cancer Research</i> , 2019 , 79, 2580-2592	10.1	42
478	Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. <i>Annals of Oncology</i> , 2018 , 29, 1554-1560	10.3	42

477	Targeting the DNA damage response in oncology: past, present and future perspectives. <i>Current Opinion in Oncology</i> , 2012 , 24, 316-24	4.2	42
476	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019 , 76, 676-685	10.2	41
475	Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. <i>European Urology</i> , 2015 , 68, 570-7	10.2	41
474	Targeting the p300/CBP Axis in Lethal Prostate Cancer. <i>Cancer Discovery</i> , 2021 , 11, 1118-1137	24.4	41
473	Therapeutics targeting signal transduction for patients with colorectal carcinoma. <i>British Medical Bulletin</i> , 2002 , 64, 227-54	5.4	40
472	Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2018 , 73, 727-735	10.2	40
471	Safety and efficacy of multipolar pulmonary vein ablation catheter vs. irrigated radiofrequency ablation for paroxysmal atrial fibrillation: a randomized multicentre trial. <i>Europace</i> , 2014 , 16, 1145-53	3.9	39
470	First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2580-2580	2.2	39
469	Prostate carcinogenesis: inflammatory storms. <i>Nature Reviews Cancer</i> , 2020 , 20, 455-469	31.3	38
468	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2016 , 2, 471-80	13.4	38
467	The promise of circulating tumor cell analysis in cancer management. <i>Genome Biology</i> , 2014 , 15, 448	18.3	38
466	Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. <i>Cancer and Metastasis Reviews</i> , 2014 , 33, 555-66	9.6	38
465	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies. <i>Investigational New Drugs</i> , 2015 , 33, 679-90	4.3	38
464	First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2013 , 19, 5494-504	12.9	38
463	Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 145-145	2.2	38
462	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with - and Non-Mutant Cancers. <i>Cancer Discovery</i> , 2020 , 10, 1528-1543	24.4	37
461	Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 1653-1654	59.2	37
460	Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients. <i>Oncotarget</i> , 2018 , 9, 19283-19293	3.3	37

459	The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. <i>Clinical Cancer Research</i> , 2017 , 23, 1967-1973	12.9	36
458	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 165-74	3.5	36
457	Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. <i>PLoS ONE</i> , 2011 , 6, e27419	3.7	36
456	Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1220-1228	12.9	36
455	Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. <i>Radiology</i> , 2016 , 280, 151-60	20.5	36
454	Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. <i>European Urology</i> , 2015 , 67, 866-73	10.2	35
453	Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. <i>Cancer Research</i> , 2017 , 77, 4745-4754	10.1	35
452	Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer. <i>Annual Review of Medicine</i> , 2013 , 64, 1-13	17.4	35
451	Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 911-9	3.5	35
450	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. <i>British Journal of Cancer</i> , 2018 , 118, 1425-1433	8.7	35
449	Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. <i>Prostate Cancer and Prostatic Diseases</i> , 2017 , 20, 221-227	6.2	34
448	Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. <i>Oncogene</i> , 2019 , 38, 5700-5724	9.2	34
447	Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. <i>Cancer Treatment Reviews</i> , 2014 , 40, 170-7	14.4	34
446	Targeting the HGF/c-Met axis: state of play. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 1077-9	6.1	34
445	Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. <i>Radiology</i> , 2017 , 284, 88-99	20.5	33
444	The molecular underpinnings of prostate cancer: impacts on management and pathology practice. <i>Journal of Pathology</i> , 2017 , 241, 173-182	9.4	33
443	Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. <i>Journal of Clinical Oncology</i> , 2003 , 21, 203-10	2.2	33
442	Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. <i>Clinical Cancer Research</i> , 2015 , 21, 1305-12	12.9	32

441	Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. <i>European Urology</i> , 2015 , 67, 310-8	10.2	32
440	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 694-701	13.4	32
439	Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. <i>Drug Discovery Today</i> , 2012 , 17, 221-6	8.8	31
438	Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival. <i>British Journal of Cancer</i> , 2020 , 122, 801-811	8.7	30
437	Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). <i>BJU International</i> , 2015 , 116, 880-7	5.6	30
436	Abiraterone acetate is well tolerated without concomitant use of corticosteroids. <i>Journal of Clinical Oncology</i> , 2010 , 28, e560-1; author reply e562	2.2	30
435	Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , 2002 , 20, 96-109	2.2	30
434	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2020 , 31, 619-625	10.3	29
433	Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 1925-34	12.9	29
432	Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA1-LBA1	2.2	29
431	Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016 , 2, 488-498	5.1	29
430	Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. <i>Clinical Cancer Research</i> , 2015 , 21, 1869-76	12.9	28
429	Management of metastatic castration-resistant prostate cancer: recent advances. <i>Drugs</i> , 2012 , 72, 1011-28	12.1	28
428	Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 1020-7	2.9	28
427	From darkness to light with biomarkers in early clinical trials of cancer drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 131-3	6.1	28
426	TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5005-5005	2.2	28
425	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. <i>Science</i> , 2021 , 374, 216-224	33.3	28
424	Diverse Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1965-1976	12.9	28

423	A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). <i>Journal of Clinical Oncology</i> , 2009 , 27, 3503-3503	2.2	27
422	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2021 , 398, 131-142	4 ⁰	27
421	Is there an antiandrogen withdrawal syndrome with enzalutamide?. <i>BJU International</i> , 2015 , 115, 373-80	5.6	26
420	Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. <i>Cancer</i> , 2017 , 123, 253-262	6.4	26
419	Molecular pathology and prostate cancer therapeutics: from biology to bedside. <i>Journal of Pathology</i> , 2014 , 232, 178-84	9.4	26
418	Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. <i>BJU International</i> , 2013 , 111, 697-9	5.6	26
417	MDV3100 for the treatment of prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 227-33	5.9	26
416	First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. <i>British Journal of Cancer</i> , 2020 , 123, 1730-1736	8.7	26
415	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. <i>European Urology</i> , 2019 , 75, 929-937	10.2	26
414	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 687-697	12.9	26
413	Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. <i>European Urology</i> , 2015 , 67, 223-30	10.2	25
412	Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016 , 70, 438-44	10.2	25
411	PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. <i>Drugs</i> , 2012 , 72, 1579-90	12.1	25
410	Belinostat: clinical applications in solid tumors and lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1723-32	5.9	25
409	Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA4518-LBA4518	2.2	25
408	Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6-6	2.2	25
407	Phase III non-inferiority study of cabazitaxel (C) 20 mg/m ² (C20) versus 25 mg/m ² (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5008-5008	2.2	25
406	Reovirus: Rationale and clinical trial update. <i>Current Opinion in Molecular Therapeutics</i> , 2009 , 11, 532-9		25

405	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features. <i>Investigative Radiology</i> , 2018 , 53, 96-102	10.1	24
404	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. <i>Radiology</i> , 2019 , 292, 273-286	20.5	24
403	Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2012 , 360, 68-75	4.4	24
402	Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. <i>Future Oncology</i> , 2014 , 10, 219-31	3.6	24
401	Novel drugs targeting the androgen receptor pathway in prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2014 , 33, 567-79	9.6	24
400	A first-in-man phase I and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2009 , 15, 4978-85	12.9	24
399	A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 425-9	3.5	24
398	Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. <i>Clinical Cancer Research</i> , 2011 , 17, 5188-96	12.9	24
397	Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee. <i>British Journal of Cancer</i> , 1999 , 80, 1786-91	8.7	24
396	Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA8-LBA8	2.2	24
395	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , 2021 , 79, 200-211	10.2	24
394	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. <i>Lancet Oncology</i> , 2021 , 22, 1250-1264	21.7	24
393	Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. <i>Cancer</i> , 2017 , 123, 2303-2311	6.4	23
392	Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e205-e208	3.3	23
391	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. <i>European Urology Oncology</i> , 2018 , 1, 151-159	6.7	23
390	Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. <i>ELife</i> , 2017 , 6,	8.9	23
389	A study of motivations and expectations of patients seen in phase 1 oncology clinics. <i>Cancer</i> , 2016 , 122, 3501-3508	6.4	23
388	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. <i>Clinical Cancer Research</i> , 2017 , 23, 6070-6077	12.9	22

387	Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1293-304	5.9	22
386	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 280-284	3.8	22
385	Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019 , 76, 843-851	10.2	21
384	Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. <i>Oncologist</i> , 2011 , 16, 1487-97	5.7	21
383	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. <i>Journal of Clinical Investigation</i> , 2020 , 130, 5875-5892	15.9	21
382	Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 139-139	2.2	21
381	Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2504-2504	2.2	21
380	First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3007-3007	2.2	21
379	KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 100-100	2.2	21
378	is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition. <i>Oncotarget</i> , 2018 , 9, 7604-7615	3.3	21
377	Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 485-493	3.3	21
376	A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015 , 4, 277-85	4.5	20
375	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. <i>European Urology</i> , 2016 , 69, 924-32	10.2	20
374	Cabazitaxel in metastatic castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1129-36	3.5	20
373	Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. <i>EPMA Journal</i> , 2012 , 3, 3	8.8	20
372	Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7522-7522	2.2	20
371	Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5005-5005	2.2	20
370	Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , 2017 , 72, 10-13	10.2	19

369	Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin. <i>Histopathology</i> , 2015 , 66, 898-901	7.3	19
368	A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2015 , 51, 2275-84	7.5	19
367	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. <i>Annals of Oncology</i> , 2017 , 28, 90-95	10.3	19
366	External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone. <i>European Urology</i> , 2014 , 66, 8-11	10.2	19
365	The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5000-5000	2.2	19
364	Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016 , 22, 353-356	2.2	19
363	Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. <i>European Urology</i> , 2019 , 76, 306-312	10.2	19
362	Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 610-617.e3	3.3	18
361	LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2020 , 31, S1153-S1154	10.3	18
360	Health economic impact of liquid biopsies in cancer management. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018 , 18, 593-599	2.2	18
359	New treatment developments applied to elderly patients with advanced prostate cancer. <i>Cancer Treatment Reviews</i> , 2013 , 39, 578-83	14.4	18
358	Targeting insulin-like growth factor signaling: rational combination strategies. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 2447-9	6.1	18
357	Revisiting the role of antiandrogen strategies in ovarian cancer. <i>Oncologist</i> , 2011 , 16, 1413-21	5.7	18
356	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.. <i>Lancet, The</i> , 2021 ,	4.0	18
355	Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2506-2506	2.2	18
354	Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. <i>Lancet Oncology, The</i> , 2020 , 21, 1478-1488	21.7	18
353	Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress. <i>Cancer Discovery</i> , 2011 , 1, 207-12	24.4	17
352	Reporting the capture efficiency of a filter-based microdevice: a CTC is not a CTC unless it is CD45 negative--letter. <i>Clinical Cancer Research</i> , 2011 , 17, 3048-9; author reply 3050	12.9	17

351	A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2514-2514	2.2	17
350	Characterizing CDK12-Mutated Prostate Cancers. <i>Clinical Cancer Research</i> , 2021 , 27, 566-574	12.9	17
349	Hypoxia and Noncoding RNAs in Taxane Resistance. <i>Trends in Pharmacological Sciences</i> , 2018 , 39, 695-709	3.2	16
348	Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 909-16	3.5	16
347	Agents that target androgen synthesis in castration-resistant prostate cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013 , 19, 34-42	2.2	16
346	Granulocyte macrophage colony-stimulating factor and interleukin-3 regulate chemokine and chemokine receptor expression in bone marrow macrophages. <i>Experimental Hematology</i> , 1999 , 27, 1735-45	3.1	16
345	Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1411-141	2.2	16
344	Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e801-e807	3.3	15
343	Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 4280-2	12.9	15
342	Application of Liquid Biopsies in Cancer Targeted Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 745-747	6.1	15
341	Reovirus therapy in cancer: has the orphan virus found a home?. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1925-35	5.9	15
340	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. <i>Cancer Discovery</i> , 2021 , 11, 2812-2827	24.4	15
339	Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. <i>European Urology Oncology</i> , 2018 , 1, 71-77	6.7	14
338	Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. <i>BJU International</i> , 2012 , 110, 658-67	5.6	14
337	Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 1213-22	3.5	14
336	Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e197-203	7.1	14
335	Beyond hormone therapy for prostate cancer with PARP inhibitors. <i>Cancer Cell</i> , 2011 , 19, 573-4	24.3	14
334	Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2011 , 71, 1264-75	4.2	14

333	The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3987-4005	15.9	14
332	The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality. <i>Trends in Cancer</i> , 2016 , 2, 646-656	12.5	14
331	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1412-24	6.1	14
330	Reply to J. Veeck et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e565-e566	2.2	13
329	Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7-7	2.2	13
328	Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5035-5035	2.2	13
327	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology, The</i> , 2020 , 21, 1513-1525	21.7	13
326	Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 678-684.e1	3.3	12
325	A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. <i>BMC Medicine</i> , 2015 , 13, 201	11.4	12
324	A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. <i>PLoS ONE</i> , 2017 , 12, e0186106	3.7	12
323	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. <i>European Urology Focus</i> , 2018 , 4, 235-244	5.1	12
322	Therapeutic options for advanced prostate cancer: 2011 update. <i>Current Urology Reports</i> , 2012 , 13, 170-8.9		12
321	Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 423-9	3.5	12
320	A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2007 , 13, 532-9	12.9	12
319	D7-02: Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S410	8.9	12
318	Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 171-171	2.2	12
317	Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 15-15	2.2	12
316	Immunotherapy for lethal prostate cancer. <i>Nature Reviews Urology</i> , 2019 , 16, 69-70	5.5	12

315	Targeting extra-gonadal androgens in castration-resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015 , 145, 157-63	5.1	11
314	CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 4992-5	12.9	11
313	Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020 , 122, 1324-1332	8.7	11
312	Enzalutamide in European and North American men participating in the AFFIRM trial. <i>BJU International</i> , 2015 , 115, 41-9	5.6	11
311	Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2077-8	6.1	11
310	Reovirus and other oncolytic viruses for the targeted treatment of cancer. <i>Targeted Oncology</i> , 2006 , 1, 130-150	5	11
309	Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5009-5009	2.2	11
308	Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail. <i>JAMA Oncology</i> , 2018 , 4, 1187-1188	13.4	11
307	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 4624-4633	12.9	10
306	A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. <i>PLoS ONE</i> , 2018 , 13, e0193689	3.7	10
305	Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer. <i>Clinical Chemistry</i> , 2013 , 59, 75-84	5.5	10
304	Cabazitaxel for castration-resistant prostate cancer [Authors' reply. <i>Lancet, The</i> , 2011 , 377, 122-123	40	10
303	Early oncology clinical trial design in the era of molecular-targeted agents. <i>Future Oncology</i> , 2010 , 6, 1339-52	3.6	10
302	Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients 2015 ,		10
301	Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations 2016 ,		10
300	First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5552-5552	2.2	10
299	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. <i>JAMA Oncology</i> , 2020 , 6, 217-225	13.4	10
298	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. <i>European Urology Oncology</i> , 2020 , 3, 176-182	6.7	10

297	Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2182-2184	2.2	9
296	RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses. <i>British Journal of Cancer</i> , 2017 , 117, 954-964	8.7	9
295	Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 155-155	2.2	9
294	Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5017-5017	2.2	9
293	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology, The</i> , 2021 , 22, 298-301	21.7	9
292	RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease. <i>Cancer Discovery</i> , 2021 , 11, 2334-2353	24.4	9
291	Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2315-2323	6.1	8
290	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in -Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1396-1404	6.1	8
289	Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2012 , 30, 316-26	4.3	8
288	Prostate cancer: evolution or revolution?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3595-8	2.2	8
287	Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 184-184	2.2	8
286	An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2503-2503	2.2	8
285	PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS5091-TPS5091	2.2	8
284	Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 216-216	2.2	8
283	TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRM) and metastatic castration-resistant prostate cancer (mCRPC) Updated interim analysis (IA).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5566-5566	2.2	8
282	Prostate Cancer 2020: "The Times They Are a'Changing". <i>Cancer Cell</i> , 2020 , 38, 25-27	24.3	8
281	What have we learned from exceptional tumour responses?: Review and perspectives. <i>Current Opinion in Oncology</i> , 2015 , 27, 267-75	4.2	7
280	Flexible trial design in practice Dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. <i>Trials</i> , 2011 , 12,	2.8	7

279	Abstract C295: Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. 2013 ,		7
278	Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 17-17	2.2	7
277	A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4511-4511	2.2	7
276	Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 16-16	2.2	7
275	A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2570-2570	2.2	7
274	Patterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8556-8556	2.2	7
273	KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5543-5543	2.2	7
272	KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 102-102	2.2	7
271	Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	7
270	Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , 2021 , 27, 3602-3609	12.9	7
269	Visualizing whole-body treatment response heterogeneity using multi-parametric magnetic resonance imaging. <i>Journal of Algorithms and Computational Technology</i> , 2016 , 10, 290-301	0.7	7
268	PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. <i>Annals of Oncology</i> , 2019 , 30, ix188-ix189	10.3	7
267	PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 13-13	2.2	7
266	Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 27-27	2.2	7
265	Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. <i>ESMO Open</i> , 2017 , 2, e000101	6	6
264	A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 17-27	3.5	6
263	Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. <i>Gastric Cancer</i> , 2014 , 17, 621-629	7.6	6
262	A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies. <i>Prostate</i> , 2009 , 69, 1507-20	4.2	6

261	Participation of patients with gynecological cancer in phase I clinical trials: two years experience in a major cancer center. <i>Gynecologic Oncology</i> , 2007 , 104, 551-6	4.9	6
260	A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2006 , 12, 2841-8	12.9	6
259	703 POSTER A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor. <i>European Journal of Cancer, Supplement</i> , 2007 , 5, 108	1.6	6
258	CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. <i>Journal of Clinical Investigation</i> , 2020 , 130, 2435-2450	15.9	6
257	Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC). <i>Journal of Clinical Oncology</i> , 2007 , 25, 5135-5135	2.2	6
256	KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 103-103	2.2	6
255	Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 182-182	2.2	6
254	Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V β V α T cell-mediated antitumor immune response. <i>Science Translational Medicine</i> , 2021 , 13, eabj0835	17.5	6
253	Genetic Analysis of Circulating Tumour Cells. <i>Recent Results in Cancer Research</i> , 2020 , 215, 57-76	1.5	6
252	Targeted α -Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1838-1839	8.9	6
251	Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2431-2	2.2	6
250	Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. <i>European Urology Oncology</i> , 2020 , 3, 540-543	6.7	6
249	Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 438-446	12.9	6
248	Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors. <i>Oncologist</i> , 2015 , 20, 368-9	5.7	5
247	Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?. <i>European Urology Focus</i> , 2021 , 7, 752-763	5.1	5
246	Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab 2020 , 8,		5
245	Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. <i>Clinical Cancer Research</i> , 2020 , 26, 4805-4813	12.9	5
244	Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. <i>European Journal of Cancer</i> , 2018 , 101, 55-61	7.5	5

243	Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2018 , 12, 339-343	2.6	5
242	Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer. <i>Value in Health</i> , 2017 , 20, 1411-1419	3.3	5
241	A Randomized Phase 3 Study Comparing First-Line Docetaxel/Prednisone (Dp) to Dp Plus Custirsen in Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc). <i>Annals of Oncology</i> , 2014 , 25, iv256	10.3	5
240	7015 POSTER DISCUSSION Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel [Results From the COU-AA-301 Phase 3 Study. <i>European Journal of Cancer</i> , 2011 , 47, S488-S489	7.5	5
239	Quantitative Analysis of Circulating Tumor Cells as a Survival Predictor in Metastatic Castration-Resistant Prostate Cancer: Missing Parts in a Superb Study: Table 1.. <i>Clinical Cancer Research</i> , 2009 , 15, 1504.2-1505	12.9	5
238	Pharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3507-3507	2.2	5
237	A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2566-2566	2.2	5
236	Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5014-5014	2.2	5
235	Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5036-5036	2.2	5
234	The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 187-187	2.2	5
233	Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5027-5027	2.2	5
232	Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5526-5526	2.2	5
231	Reappraisal of glucocorticoids in castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014 , 16, 666	2.8	5
230	Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS5088-TPS5088	2.2	5
229	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. <i>Cancer Research</i> , 2021 , 81, 1087-1100	10.1	5
228	Cabozantinib-Getting Under the Skin of Cutaneous Toxicity. <i>JAMA Oncology</i> , 2015 , 1, 535-6	13.4	4
227	621P Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update. <i>Annals of Oncology</i> , 2020 , 31, S513-S514	10.3	4
226	Circulating cell-free DNA: Translating prostate cancer genomics into clinical care. <i>Molecular Aspects of Medicine</i> , 2020 , 72, 100837	16.7	4

225	Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 44-44	2.2	4
224	Phase I dose escalation study of 3-weekly BI 836845, a fully human, affinity optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2622-2622	2.2	4
223	Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 14-14	2.2	4
222	Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2582-2582	2.2	4
221	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA5003-LBA5003	2.2	4
220	Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5013-5013	2.2	4
219	A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS391-TPS391	2.2	4
218	BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3618-3618	2.2	4
217	Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5539-5539	2.2	4
216	PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 134-134	2.2	4
215	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. <i>International Journal of Cancer</i> , 2021 ,	7.5	4
214	6100 Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. <i>Annals of Oncology</i> , 2020 , 31, 8508	10.3	4
213	Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 454-467	19.4	4
212	Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5013-5013	2.2	4
211	Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2562-2562	2.2	4
210	Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. <i>Clinical Cancer Research</i> , 2021 , 27, 2340-2351	12.9	4
209	A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3K Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
208	Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience. <i>Journal of Neuro-Oncology</i> , 2018 , 139, 107-116	4.8	3

207	Second-generation antiandrogens in nonmetastatic CRPC. <i>Nature Reviews Urology</i> , 2018 , 15, 342-344	5.5	3
206	Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>Eur Urol</i> 2018 , 73, 178-211. <i>European Urology</i> , 2018 , 73, e32-e33	10.2	3
205	Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents. <i>Drugs</i> , 2016 , 76, 421-30	12.1	3
204	Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476). <i>Annals of Oncology</i> , 2017 , 28, v620	10.3	3
203	7105 POSTER DISCUSSION Belinostat in Combination With Carboplatin and Paclitaxel (BelCaP) for Treatment of Bladder Cancer □A Pharmacokinetic Study of Exposure to Belinostat and Its Metabolites. <i>European Journal of Cancer</i> , 2011 , 47, S506	7.5	3
202	Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S189-94	7.5	3
201	Horizon scanning for novel therapeutics for the treatment of prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1487-502	5.9	3
200	1204 A Phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 121	1.6	3
199	Abstract 2433: In vitro and in vivo antitumor activity of the next generation HSP90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models. 2013 ,		3
198	Abstract 4679: Mismatch repair defects in lethal prostate cancer 2017 ,		3
197	Abstract 993: Diagnostic leukapheresis (DLA): Molecular characterisation and organoid culture of circulating tumor cells (CTC) from metastatic castration resistant prostate cancer (mCRPC) 2017 ,		3
196	A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following	2.2	3
195	Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e13559-e13559	2.2	3
194	Effect of concomitant medication use on outcomes of treatment and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16045-e16045	2.2	3
193	A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS5097-TPS5097	2.2	3
192	Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 20-20	2.2	3
191	CK- and small nuclear size circulating tumor cell (CTCs) phenotypes in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 209-209	2.2	3
190	A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 70-70	2.2	3

189	Sequential monitoring and characterization of circulating tumor cells (CTCs) using the epic sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 78-78	2.2	3
188	A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC (TF-ADC) in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2570-2570	2.2	3
187	Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV) Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS5069-TPS5069	2.2	3
186	Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 215-215	2.2	3
185	Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5014-5014	2.2	3
184	High neutrophil-to-lymphocyte ratio (NLR), myeloid-derived suppressor cells (MDSCs) and resistance to corticosteroid therapy (CST) in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5076-5076	2.2	3
183	Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5007-5007	2.2	3
182	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 135-135	2.2	3
181	Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5070-5070	2.2	3
180	Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5010-5010	2.2	3
179	Circulating tumor DNA (ctDNA) dynamics associate with treatment response and radiological progression-free survival (rPFS): Analyses from a randomized phase II trial in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5508-5508	2.2	3
178	Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5544-5544	2.2	3
177	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. <i>Oncotarget</i> , 2017 , 8, 104430-104443	3.3	3
176	Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5545-5545	2.2	3
175	Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). <i>Investigational New Drugs</i> , 2020 , 38, 1117-1128	4.3	3
174	Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). <i>Investigational New Drugs</i> , 2020 , 38, 1096-1107	4.3	3
173	Targeting defective DNA repair in prostate cancer. <i>Current Opinion in Oncology</i> , 2020 , 32, 503-509	4.2	3
172	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. <i>Cancers</i> , 2021 , 13,	6.6	3

171	Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. <i>European Urology Focus</i> , 2021 ,	5.1	3
170	Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021 , 41, e190-e202	7.1	3
169	Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. <i>European Urology</i> , 2021 , 80, 243-253	10.2	3
168	A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. <i>Annual Review of Pharmacology and Toxicology</i> , 2021 ,	17.9	3
167	Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. <i>European Urology</i> , 2021 , 80, 497-506 ^{10.2}	10.2	3
166	A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 757-766	3.5	2
165	343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts). <i>European Journal of Cancer</i> , 2015 , 51, S68	7.5	2
164	Management of patients with castration-resistant disease. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 1243-60, ix	3.1	2
163	MP87-18 ASSESSMENT OF CORTICOSTEROID (CS)-ASSOCIATED ADVERSE EVENTS (AES) WITH LONG-TERM (LT) EXPOSURE TO LOW-DOSE PREDNISONE (P) GIVEN WITH ABIRATERONE ACETATE (AA) TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS). <i>Journal of Urology</i> , 2015 , 193,	2.5	2
162	Response Rates and Outcomes with Enzalutamide for Patients with Metastatic Castration Resistant Prostate Cancer and Visceral Disease in the Prevail Trial. <i>Annals of Oncology</i> , 2014 , 25, iv262	10.3	2
161	A Phase 1/2 Study of At13387, a Heat Shock Protein 90 (Hsp90) Inhibitor in Combination with Abiraterone Acetate (Aa) and Prednisone (P) in Patients (Pts) with Castration-Resistant Prostate Cancer (Mcrpc) No Longer Responding to Aa. <i>Annals of Oncology</i> , 2014 , 25, iv267	10.3	2
160	1248 POSTER A Phase I Study Evaluating GDC-0941, a Pan-phosphoinositide-3 Kinase (PI3K) Inhibitor, in Patients (pts) With Advanced Solid Tumours, Multiple Myeloma, and PIK3Ca Mutant (mt) Tumours. <i>European Journal of Cancer</i> , 2011 , 47, S159	7.5	2
159	First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers. <i>Gynecologic Oncology</i> , 2011 , 120, S5-S6	4.9	2
158	Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 65, 167-75	3.5	2
157	573 POSTER Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumors with mutated EGFR. <i>European Journal of Cancer, Supplement</i> , 2006 , 4, 173-174	1.6	2
156	Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	2
155	316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A 2020 , 8, A342-A342		2
154	Abstract CT328: Exploratory genetic analysis of tumors from a phase I/II dose escalation study of GSK2636771 in patients (pts) with PTEN deficient advanced tumors 2015 ,		2

153	Abstract 2243: Characterization of PD-L1 expression on circulating tumor cells (CTCs) isolated with a label-free inertial microfluidic system from advanced non-small cell lung cancer patients (NSCLC pts) 2016 ,		2
152	Final results of a phase I study of wild-type oncolytic reovirus administered intravenously to patients with advanced cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3572-3572	2.2	2
151	First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5052-5052	2.2	2
150	A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 123-123	2.2	2
149	Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 14-14	2.2	2
148	Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 17-17	2.2	2
147	Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 20-20	2.2	2
146	TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2607-2607	2.2	2
145	Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5007-5007	2.2	2
144	Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5042-5042	2.2	2
143	Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 21-21	2.2	2
142	Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 268-268	2.2	2
141	Clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with a post-treatment circulating tumor cell (CTC) of 0 vs CTC > 0: Post hoc analysis of COU-AA-301.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5015-5015	2.2	2
140	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA5003-LBA5003	2.2	2
139	Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 141-141	2.2	2
138	Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5064-5064	2.2	2
137	PIPA: A phase Ib study of selective I isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor tasisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3087-3087	2.2	2
136	Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5070-5070	2.2	2

135	A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS5087-TPS5087 ^{2,3}	2
134	HER3 is an Actionable Target in Advanced Prostate Cancer. <i>Cancer Research</i> , 2021 ,	10.1 2
133	Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5550-5550	2.2 2
132	Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers. <i>Journal of Clinical Oncology</i> , 2009 , 27, e14519-e14519	2.2 2
131	625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update. <i>Annals of Oncology</i> , 2020 , 31, S516-S517	10.3 2
130	A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic. <i>Lancet Oncology</i> , 2020 , 21, 889-891	21.7 2
129	A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021 , 124, 391-398	8.7 2
128	Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience. <i>Cancer Treatment and Research Communications</i> , 2021 , 27, 100309	2 2
127	Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. <i>Clinical Oncology</i> , 2018 , 30, 185-191	2.8 2
126	Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre. <i>British Journal of Cancer</i> , 2018 , 119, 922-927	8.7 2
125	Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Targeted Oncology</i> , 2021 , 16, 613-623	5 2
124	Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. <i>ESMO Open</i> , 2021 , 6, 100241	6 2
123	H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2114324119 ^{11.5}	2
122	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa003	4.6 1
121	Elucidating Durable Responses to Immune Checkpoint Inhibition. <i>European Urology</i> , 2020 , 78, 639-641	10.2 1
120	785 EFFICACY OUTCOMES BY BASELINE PROSTATE-SPECIFIC ANTIGEN (PSA): RESULTS FROM THE PHASE 3 AFFIRM TRIAL. <i>Journal of Urology</i> , 2013 , 189,	2.5 1
119	713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL. <i>Journal of Urology</i> , 2013 , 189,	2.5 1
118	715 CABAZITAXEL FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): FINAL QUALITY OF LIFE (QOL) RESULTS WITH SAFETY DATA FROM THE UNITED KINGDOM (UK) EARLY ACCESS PROGRAMME (EAP) (NCT01254279). <i>Journal of Urology</i> , 2013 , 189,	2.5 1

117	Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033	10.2	1
116	PI-05 LATE-BREAKING ABSTRACT: THE PREVAIL STUDY: PRIMARY AND NON-VISCERAL / VISCERAL DISEASE SUBGROUP RESULTS FOR ENZALUTAMIDE-TREATED MEN WITH METASTATIC PROSTATE CANCER (MPC) THAT HAD PROGRESSED ON ADT. <i>Journal of Urology</i> , 2014 , 191,	2.5	1
115	Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience. <i>British Journal of Cancer</i> , 2008 , 99, 1365-1365	8.7	1
114	388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors 2020 , 8, A413-A413		1
113	Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from patients with castrate-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 62-62	2.2	1
112	Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 91-91	2.2	1
111	Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5054-5054	2.2	1
110	Characterization of ovarian cancer long-term responders on olaparib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5534-5534	2.2	1
109	Is there an anti-androgen withdrawal effect with enzalutamide?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 200-200	2.2	1
108	Safety, efficacy and survival of patients (pts) with primary CNS tumors in phase 1 (Ph1) trials: A 12-year single institution experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2043-2043	2.2	1
107	Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5009-5009	2.2	1
106	Clinical characteristics of metastatic castration-resistant prostate cancer (mCRPC) patients with DNA repair (DNAr) defects.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5028-5028	2.2	1
105	Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant (ARMOR3-SV).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS5085-TPS5085	2.2	1
104	Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 182-182	2.2	1
103	Clinical outcomes of adolescents and young adults (AYA) with advanced solid tumors participating in phase I trials.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10536-10536	2.2	1
102	PSMA heterogeneity and DNA repair defects in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5002-5002	2.2	1
101	Impact of olaparib vs physician's choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5538-5538	2.2	1
100	Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5559-5559	2.2	1

99	Consensus statement on circulating biomarkers for advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 299-299	2.2	1
98	Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5058-5058	2.2	1
97	A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2573-2573	2.2	1
96	Prostate-specific Membrane Antigen Theranostics for Prostate Cancer Care: A Need to Prove Clinical Utility. <i>European Urology Focus</i> , 2021 , 7, 231-233	5.1	1
95	Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naïve disease. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 1287-1297	2.8	1
94	An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. <i>ESMO Open</i> , 2021 , 6, 100089	6	1
93	Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. <i>Oncologist</i> , 2021 , 26, e1179-e1188	5.7	1
92	A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS3153-TPS3153	2.2	1
91	HER3 expression and MEK activation in non-small-cell lung carcinoma. <i>Lung Cancer Management</i> , 2021 , 10, LMT48	2.6	1
90	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e577-83	7.1	1
89	Reply to M. Horiguchi et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 826-827	2.2	1
88	Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation. <i>Metabolomics</i> , 2020 , 16, 50	4.7	0
87	Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 169-169	2.2	0
86	CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5569-5569	2.2	0
85	Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4515-4515	2.2	0
84	Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5047-5047	2.2	0
83	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021 , 79, 736-746	10.2	0
82	The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre international retreat. <i>Canadian Urological Association Journal</i> , 2021 , 15, E623-E629	1.2	0

81	AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification. <i>Cancer Treatment and Research Communications</i> , 2021 , 28, 100218	2	o
80	CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 161-161	2.2	o
79	Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT). <i>BMJ Open</i> , 2021 , 11, e049217	3	o
78	TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)Exploration of germline DDR alteration landscape and potential associations with antitumor activity.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 157-157	2.2	o
77	A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.. <i>Molecular Cancer</i> , 2022 , 21, 82	42.1	o
76	Neutropenia, neutrophilia, and neutrophil/lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 175883592211000	5.4	o
75	Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). <i>Eur Urol</i> . In press.	10.2	
74	https://doi.org/10.1016/j.eururo.2018.02.013 . <i>European Urology</i> , 2018 , 74, e69-e70 New Therapies in Hormone Relapsed Disease 2014 , 265-286		
73	P623RGS-1 modulates leukocyte trafficking in atherosclerosis and aortic aneurysm formation through chemokine receptor desensitisation. <i>Cardiovascular Research</i> , 2014 , 103, S113.1-S113	9.9	
72	Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>Eur Urol</i> . In press.	10.2	
71	Heterogeneity of advanced prostate cancer: clinical implications of genomics. <i>Trends in Urology & Men's Health</i> , 2017 , 8, 24-27	0.3	
70	Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. <i>European Journal of Cancer</i> , 2014 , 50, 1042-3	7.5	
69	Drugs for Cancer 2013 , 270-285		
68	168 Circulating tumour cells as biomarkers in clinical trials. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 42-43	1.6	
67	Pharmacogenomics of Non-Small Cell Lung Cancer. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2007 , 5, 228-234		
66	389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors 2020 , 8, A414-A414		
65	Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? Against. <i>European Oncology and Haematology</i> , 2018 , 14, 14	0.1	
64	Clinical outcome of patients with germline DNA repair mutations: Results from a retrospective international study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 218-218	2.2	

63	Clinical and economic burden of serious adverse events (SAEs) in an early phase trials unit.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18890-e18890	2.2
62	A novel approach to mine the Veterans Administration Informatics and Computing Infrastructure (VINCI) allows one to assess the efficacy of cancer therapies: Abiraterone and enzalutamide in Veterans with metastatic prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6586-6586	2.2
61	The prognostic and predictive value of AR-V7 quantification in mCRPC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12026-12026	2.2
60	Early changes in PSA and association with outcomes in mCRPC patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5063-5063	2.2
59	Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3237-3237	2.2
58	Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 151-151	2.2
57	Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18175-e18175	2.2
56	Distinct radiological patterns of drug-induced pneumonitis (R-DIP) in early-phase clinical trials and predictive factors affecting outcome: A 10-year systematic review from the Royal Marsden Hospital Phase I Drug Development Unit experience.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3088-3088	2.2
55	Pain progression at initiation of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of PROSELICA.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5558-5558	2.2
54	Primary malignant brain tumours (PMBT) in phase I studies: Barriers to treatment and patient outcomes.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2024-2024	2.2
53	What factors influence advanced ovarian cancer patient (AOC pt) outcomes to phase I trial treatments?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5560-5560	2.2
52	Complications of hyperglycemia in phase 1 trials targeting the PI3K-akt-mTOR (PAM) pathway.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2612-2612	2.2
51	Targeted deep sequencing from circulating plasma DNA as a multipurpose biomarker in pts (pts) referred for phase I trials.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11051-11051	2.2
50	Prognostic significance of the neutrophil-lymphocyte ratio (NLR) in phase 1 clinical trial patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3037-3037	2.2
49	Predictive factors of survival for patients with bladder cancer (BC) in phase I clinical trials.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15525-e15525	2.2
48	A study of risk of infection with drugs targeting the PI3 kinase (PI3K), AKT, and mTOR pathway.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2608-2608	2.2
47	Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5013-5013	2.2
46	Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 142-142	2.2

- 45 Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC): PK, safety and PR testing results from the dose escalation cohort.. *Journal of Clinical Oncology*, **2015**, 33, 5051-5051 2.2
- 44 Clinical outcomes in advanced cervical cancer (CC) and endometrial cancer (EC) patients (pts) treated in phase I trials of novel molecularly targeted agents (MTAs).. *Journal of Clinical Oncology*, **2015**, 33, 5596-5596 2.2
- 43 Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.. *Journal of Clinical Oncology*, **2016**, 34, 273-273 2.2
- 42 PSA levels after dexamethasone withdrawal (DW) in castration resistant prostate cancer (CRPC).. *Journal of Clinical Oncology*, **2016**, 34, 278-278 2.2
- 41 Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.. *Journal of Clinical Oncology*, **2016**, 34, 213-213 2.2
- 40 Interrogating metastatic prostate cancer treatment switch decisions.. *Journal of Clinical Oncology*, **2016**, 34, 296-296 2.2
- 39 Loco-regional treatment (LRT) for M1 at diagnosis prostate cancer (PCa) patients (pts) and impact on overall survival (OS): A retrospective analysis.. *Journal of Clinical Oncology*, **2016**, 34, 280-280 2.2
- 38 Cabazitaxel for the Treatment of Prostate Cancer **2016**, 187-214
- 37 Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302.. *Journal of Clinical Oncology*, **2016**, 34, 168-168 2.2
- 36 Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.. *Journal of Clinical Oncology*, **2016**, 34, 266-266 2.2
- 35 Incidence, severity and factors associated with diarrhoea in phase I oncology studies: experience of 1002 consecutive cases.. *Journal of Clinical Oncology*, **2016**, 34, 2568-2568 2.2
- 34 Clinical outcomes of advanced small cell lung cancer patients (SCLC pts) on phase I (Ph I) trials in the Drug Development Unit (DDU) at the Royal Marsden Hospital (RMH).. *Journal of Clinical Oncology*, **2016**, 34, e14048-e14048 2.2
- 33 Quantifying patients' motivations for phase I oncology trials and how expectations change at the first clinical consultation.. *Journal of Clinical Oncology*, **2016**, 34, 10061-10061 2.2
- 32 Ultrasound guided biopsies in phase I trials: Single center experience of 350 consecutive cases.. *Journal of Clinical Oncology*, **2016**, 34, 11579-11579 2.2
- 31 Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.. *Journal of Clinical Oncology*, **2016**, 34, 5062-5062 2.2
- 30 A phase I study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients (pts) with advanced solid tumors.. *Journal of Clinical Oncology*, **2016**, 34, 2571-2571 2.2
- 29 Target-based therapeutic matching of phase I trials in patients with advanced breast cancer (BC pts) in the Royal Marsden Hospital Drug Development Unit (RMH DDU).. *Journal of Clinical Oncology*, **2016**, 34, 11508-11508 2.2
- 28 Circulating tumor cell (CTC) rise and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) with low baseline CTC counts.. *Journal of Clinical Oncology*, **2016**, 34, 5042-5042 2.2

27	Clinical and radiological characteristics of metastatic prostate cancer (mPCa) patients (pts) with liver metastases (LM) and association with overall survival (OS).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5043-5043	2.2
26	TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2571-2571	2.2
25	A phase 1/1b multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI3726 in patients with metastatic, castration-resistant prostate cancer who have received prior treatment with abiraterone or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS5088-TPS5088	2.2
24	Adherence to novel oral anticancer therapies in the phase I setting: The Royal Marsden experience.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2542-2542	2.2
23	Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5014-5014	2.2
22	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) inhibition.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5071-5071	2.2
21	Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies.. <i>Blood</i> , 2010 , 116, 1787-1787	2.2
20	Hormone treatment for prostate cancer 2011 , 46-52	
19	Correlation of oncogenic mutations in circulating cell-free DNA (cfDNA) and tumor tissue through a multiplex sequencing platform in patients under consideration for phase I trials.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 6-6	2.2
18	Prognostic value of serum androgens, by ultrasensitive assay, in metastatic castration-resistant prostate cancer (mCRPC): Phase III trial data.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 22-22	2.2
17	Outcome of patients (pts) with relapsed, advanced upper gastrointestinal (GI) carcinoma treated in a specialist oncology phase I unit.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 45-45	2.2
16	A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 24-24	2.2
15	Phase III Targeted Treatments. <i>Current Clinical Urology</i> , 2014 , 177-186	
14	PARP Inhibitors. <i>Current Clinical Urology</i> , 2014 , 253-264	
13	Predicting positive bone marrow biopsies (BMBs) in patients (PTS) with advanced prostate cancer (APC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 180-180	2.2
12	Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 222-222	2.2
11	Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. <i>Archivio Italiano Di Urologia Andrologia</i> , 2016 , 88, 72-3	1.6
10	Abiraterone for the Treatment of mCRPC 2016 , 125-155	

- 9 Reply to A. Addeo and A. Bahl. *Journal of Clinical Oncology*, **2016**, 34, 387-8 2.2
- 8 Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. *European Urology*, **2021**, 79, 170-171 10.2
- 7 SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer (mCRPC): A phase I/ randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.. *Journal of Clinical Oncology*, **2021**, 39, 107-107 2.2
- 6 Putative biomarkers of response to anti-PD-1 therapy in metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2021**, 39, 155-155 2.2
- 5 Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2020.09.024>. *European Urology*, **2021**, 79, e83-e84 10.2
- 4 Reply to C. Ren et al. *Journal of Clinical Oncology*, **2018**, 36, 2354-2356 2.2
- 3 Can Early Clinical Trials Help Deliver More Precise Cancer Care? **2018**, 115-128
- 2 BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype: Phase 2a interim results.. *Journal of Clinical Oncology*, **2022**, 40, 126-126 2.2
- 1 Selective Tumour Cell Cytotoxicity by Reoviridae: Preclinical Evidence and Clinical Trial Results 139-150